Cargando…

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells

The new combination between the nucleoside analogue gemcitabine and the cholesterol-lowering drug fluvastatin was investigated in vitro and in vivo on the human pancreatic tumour cell line MIAPaCa-2. The present study demonstrates that fluvastatin inhibits proliferation, induces apoptosis in pancrea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bocci, G, Fioravanti, A, Orlandi, P, Bernardini, N, Collecchi, P, Del Tacca, M, Danesi, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361561/ https://www.ncbi.nlm.nih.gov/pubmed/16052215 http://dx.doi.org/10.1038/sj.bjc.6602720

Ejemplares similares

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

Na(+)/H(+) exchanger regulatory factor 1 overexpression suppresses the malignant phenotype of MIAPaCa-2 pancreatic adenocarcinoma cells by downregulating Akt phosphorylation
por: Zhang, Xibo, et al.
Publicado: (2018)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Senescent Human Pancreatic Stellate Cells Secrete CXCR2 Agonist CXCLs to Promote Proliferation and Migration of Human Pancreatic Cancer AsPC-1 and MIAPaCa-2 Cell Lines
por: Takikawa, Tetsuya, et al.
Publicado: (2022)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

The role of apoptotic cell death in the radiosensitising effect of gemcitabine
por: Pauwels, B, et al.
Publicado: (2009)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
por: Singh, S, et al.
Publicado: (2010)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Curcumin–cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer
por: Rocks, N, et al.
Publicado: (2012)

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
por: Gunelli, R, et al.
Publicado: (2007)

Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
por: Patel, Girijesh Kumar, et al.
Publicado: (2017)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
por: Serova, M, et al.
Publicado: (2007)

Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells
por: Fabian, I, et al.
Publicado: (2006)

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
por: Jin, L, et al.
Publicado: (2011)

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
por: Benhadji, K A, et al.
Publicado: (2008)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
por: Lee, J-L, et al.
Publicado: (2014)

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer
por: Xu, S, et al.
Publicado: (2015)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model
por: Bhardwaj, A, et al.
Publicado: (2014)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o6elffrjckl5e3a5cg8esb265a